RSS-Feed abonnieren
DOI: 10.1055/s-2007-996038
Platelet Hemostatic Capacity (PHC) and Fibrinolytic Inhibitors during Pregnancy
Publikationsverlauf
Publikationsdatum:
06. Februar 2008 (online)
![](https://www.thieme-connect.de/media/sth/199805/lookinside/thumbnails/10.1055-s-2007-996038-1.jpg)
Abstract
Platelet hemostatic capacity (PHC) was measured in blood from pregnant patients during all three trimesters using the PFA-100™ system. Closure times were shorter with both cartridge systems during pregnancy, compared to non-pregnant controls, suggesting increased PHC. Thrombin/antithrombin (TAT) complex and prothrombin fragment 1 + 2 (F1+2) levels were elevated during pregnancy and increased over time. Also, plasma levels of plasminogen activator inhibitor 1 and 2 (PAI-1, PAI-2) increased during pregnancy. The data suggest increased coagulability during pregnancy. It is suggested that estrogen may play a role in this state of hypercoagulability. Seven days after delivery all of the measured parameters, except TAT levels, were again within normal range.
Keywords:
PFA-100™ - primary hemostasis - pregnancy - TAT - F 1+2 - PAI-1 - PAI-2 - estrogen